CY1123386T1 - Συνεργιστικες συνθεσεις που περιλαμβανουν (r)-διμιρακεταμη (1) και (s)-διμιρακεταμη (2) σε μη ρακεμικη αναλογια - Google Patents

Συνεργιστικες συνθεσεις που περιλαμβανουν (r)-διμιρακεταμη (1) και (s)-διμιρακεταμη (2) σε μη ρακεμικη αναλογια

Info

Publication number
CY1123386T1
CY1123386T1 CY20201100929T CY201100929T CY1123386T1 CY 1123386 T1 CY1123386 T1 CY 1123386T1 CY 20201100929 T CY20201100929 T CY 20201100929T CY 201100929 T CY201100929 T CY 201100929T CY 1123386 T1 CY1123386 T1 CY 1123386T1
Authority
CY
Cyprus
Prior art keywords
dimiracetam
composition
compositions including
racemic ratio
compositions
Prior art date
Application number
CY20201100929T
Other languages
English (en)
Inventor
Michael Scherz
Carlo Farina
Original Assignee
Metys Pharmaceuticals AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metys Pharmaceuticals AG filed Critical Metys Pharmaceuticals AG
Publication of CY1123386T1 publication Critical patent/CY1123386T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μία σύνθεση εναντιομερών 3,6,77a-τετραϋδρο-1Η-πυρρολο[1,5-a]ιμιδαζολ-2,5-διόνης και φαρμακευτικά αποδεκτών στερεών διαλυμάτων ή συγκρυστάλλων αυτών σε ορισμένη αναλογία, μία φαρμακευτική σύνθεση που περιλαμβάνει την εν λόγω σύνθεση, τη χρήση της ως θεραπευτικό μέσο και τη χρήση των συνθέσεων της εφεύρεσης ή των φαρμακευτικών συνθέσεων στην αγωγή και/ή την πρόληψη μίας νόσου ή διαταραχής που τυπικά και κατά προτίμηση επιλέγεται από περιφερική αισθητική νευροπάθεια, κατά προτίμηση περιφερικό νευροπαθές άλγος• σπασμούς• κατάθλιψη• ή γνωσιακή διαταραχή.
CY20201100929T 2017-05-31 2020-10-05 Συνεργιστικες συνθεσεις που περιλαμβανουν (r)-διμιρακεταμη (1) και (s)-διμιρακεταμη (2) σε μη ρακεμικη αναλογια CY1123386T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17173760 2017-05-31
PCT/EP2018/064125 WO2018219977A1 (en) 2017-05-31 2018-05-30 Synergistic compositions comprising (r)-dimiracetam (1) and (s)-dimiracetam (2) in a non-racemic ratio

Publications (1)

Publication Number Publication Date
CY1123386T1 true CY1123386T1 (el) 2021-12-31

Family

ID=59053899

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100929T CY1123386T1 (el) 2017-05-31 2020-10-05 Συνεργιστικες συνθεσεις που περιλαμβανουν (r)-διμιρακεταμη (1) και (s)-διμιρακεταμη (2) σε μη ρακεμικη αναλογια

Country Status (32)

Country Link
US (2) US10738054B2 (el)
EP (2) EP3735971A1 (el)
JP (2) JP6810983B2 (el)
KR (1) KR102269493B1 (el)
CN (1) CN110719779B (el)
AU (1) AU2018276382B2 (el)
BR (1) BR112019025006A2 (el)
CA (1) CA3061274C (el)
CL (1) CL2019003503A1 (el)
CO (1) CO2019013212A2 (el)
CY (1) CY1123386T1 (el)
DK (1) DK3534898T3 (el)
EA (1) EA201992817A1 (el)
EC (1) ECSP19085426A (el)
ES (1) ES2825498T3 (el)
GE (1) GEP20227336B (el)
HR (1) HRP20201608T1 (el)
HU (1) HUE050981T2 (el)
IL (1) IL270833B (el)
JO (1) JOP20190251A1 (el)
LT (1) LT3534898T (el)
MX (1) MX2019013897A (el)
NI (1) NI201900122A (el)
PE (1) PE20200699A1 (el)
PH (1) PH12019502580B1 (el)
PT (1) PT3534898T (el)
RS (1) RS60957B1 (el)
SG (1) SG11201909720SA (el)
SI (1) SI3534898T1 (el)
UA (1) UA125703C2 (el)
WO (1) WO2018219977A1 (el)
ZA (1) ZA201906863B (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190251A1 (ar) * 2017-05-31 2019-10-21 Metys Pharmaceuticals AG تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية
MX2021006243A (es) * 2018-12-04 2021-08-11 Metys Pharmaceuticals AG Composiciones sinergicas que comprenden (r)-2-(2-oxopirrolidin-1-i l)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporcion no racemica.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1233860B (it) 1988-02-08 1992-04-21 Isf Spa Derivati del peridroazacicloalca (1,2-a) imidazolo ad attivita' nootropa
US5200406A (en) 1988-02-08 1993-04-06 I.S.F. Societa Per Azioni Pharmaceutically useful 2,5-dioxo-1H-octahydroimidazo[1,2-A]azepines
GB9123641D0 (en) 1991-11-07 1992-01-02 Isf Spa Process
AU1400100A (en) * 1998-12-02 2000-06-19 Darwin Discovery Limited Therapeutic product and its use
EP1034826A1 (en) 1999-03-05 2000-09-13 Reuter Chemische Apparatebau Co-crystallization process
ITMI20030573A1 (it) 2003-03-24 2004-09-25 Nikem Research Srl Composti ad azione nootropica, loro preparazione,
WO2008073381A2 (en) * 2006-12-11 2008-06-19 University Of Kentucky Research Foundation Synergistic effects of combinations of nornicotine and opioids for the treatment of pain
AU2012201853B2 (en) 2007-04-16 2013-06-27 Neurotune Ag Use of dimiracetam in the treatment of chronic pain
ITMI20070770A1 (it) 2007-04-16 2008-10-17 Brane Discovery S R L Impiego di dimiracetam nel trattamento del dolore cronico
EP2215073A4 (en) 2007-10-31 2011-04-06 Merck Sharp & Dohme SLEEP MODULATION WITH NR2B RECEPTOR ANTAGONISTS
EP2098526B1 (en) 2008-02-22 2014-01-15 Neurotune AG Nitrogen-containing bicyclic compounds active on chronic pain conditions
US9125898B2 (en) 2008-11-14 2015-09-08 Neurotune Ag Acetam derivatives for pain relief
ES2473271T3 (es) 2010-07-26 2014-07-04 Neurotune Ag Proceso de preparación de dimiracetam
WO2012055057A1 (en) 2010-10-29 2012-05-03 Neurotune Ag Therapeutic use of dimiracetam to prevent the hand & foot syndrome caused by sorafenib
WO2015010217A1 (en) * 2013-07-24 2015-01-29 Neurotune Ag Dimiracetam in the treatment of depression
JOP20190251A1 (ar) 2017-05-31 2019-10-21 Metys Pharmaceuticals AG تركيبات تآزرية تشتمل على (r)-ديميراسيتام (1) و(s)-ديميراسيتام (2) بنسبة غير راسيمية

Also Published As

Publication number Publication date
DK3534898T3 (da) 2020-09-07
PH12019502580A1 (en) 2020-09-28
GEP20227336B (en) 2022-01-10
ES2825498T3 (es) 2021-05-17
WO2018219977A1 (en) 2018-12-06
IL270833A (en) 2020-01-30
CL2019003503A1 (es) 2020-04-24
PE20200699A1 (es) 2020-06-23
ECSP19085426A (es) 2020-05-29
US20200331919A1 (en) 2020-10-22
EP3534898A1 (en) 2019-09-11
RS60957B1 (sr) 2020-11-30
CA3061274A1 (en) 2018-12-06
JP6810983B2 (ja) 2021-01-13
SI3534898T1 (sl) 2020-11-30
KR20200009093A (ko) 2020-01-29
JP2021073171A (ja) 2021-05-13
PT3534898T (pt) 2020-10-06
AU2018276382B2 (en) 2021-03-25
EA201992817A1 (ru) 2020-04-06
CN110719779A (zh) 2020-01-21
SG11201909720SA (en) 2019-11-28
EP3534898B1 (en) 2020-08-05
HUE050981T2 (hu) 2021-01-28
JOP20190251A1 (ar) 2019-10-21
EP3735971A1 (en) 2020-11-11
ZA201906863B (en) 2021-02-24
MX2019013897A (es) 2020-01-20
KR102269493B1 (ko) 2021-06-25
NZ758086A (en) 2020-12-18
JP7157471B2 (ja) 2022-10-20
IL270833B (en) 2021-05-31
BR112019025006A2 (pt) 2020-06-16
CO2019013212A2 (es) 2020-01-17
AU2018276382A1 (en) 2019-10-31
UA125703C2 (uk) 2022-05-18
CN110719779B (zh) 2022-02-01
NI201900122A (es) 2020-07-01
CA3061274C (en) 2023-03-21
LT3534898T (lt) 2020-12-10
PH12019502580B1 (en) 2020-09-28
JP2020521816A (ja) 2020-07-27
US20180346472A1 (en) 2018-12-06
HRP20201608T1 (hr) 2021-01-08
US10738054B2 (en) 2020-08-11

Similar Documents

Publication Publication Date Title
CY1124084T1 (el) Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
CY1121781T1 (el) Φαρμακοτεχνικες μορφες παρατεταμενης απελευθερωσης της ρασαγιλινης και χρησεις αυτων
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
MX2020001403A (es) Nuevos derivados de quinolina.
PH12020551043A1 (en) Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
ECSP077324A (es) Amidas bicíclicas como inhibidores de cinasa
EA201691454A1 (ru) Композиции придопидина модифицированного высвобождения
CY1123386T1 (el) Συνεργιστικες συνθεσεις που περιλαμβανουν (r)-διμιρακεταμη (1) και (s)-διμιρακεταμη (2) σε μη ρακεμικη αναλογια
EA202192625A1 (ru) Лиганды псевдокиназы tyk2
CY1117174T1 (el) ΧΡΗΣΗ 24-norUDCA ΓΙΑ ΤΗΝ ΑΓΩΓΗ ΧΟΛΟΣΤΑΤΙΚΩΝ ΝΟΣΗΜΑΤΩΝ ΤΟΥ ΗΠΑΤΟΣ
CL2022001178A1 (es) Ligandos de la pseudoquinasa tyk2
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
CL2018000430A1 (es) Compuesto de hidroxitriazina y uso médico relacionado.
EA201990947A1 (ru) Замещенные производные 6-(1h-пиразол-1-ил)пиримидин-4-амина и их применение
EA202091736A1 (ru) Применение колхицина для ингибирования роста опухоли и метастазов
JOP20190178A1 (ar) تركيبة صيدلانية تتضمن مشتق أوكسازين واستخدامها في علاج أو الوقاية من مرض الزهايمر
PH12020500120A1 (en) Pharmaceutical compositions
EA202090165A1 (ru) Фармацевтическая композиция для предупреждения или лечения сердечно-сосудистых заболеваний, сопровождающихся диабетом, содержащая амлодипин, лозартан и розувастатин, и комбинированный препарат, содержащий ее
ZA202104167B (en) Compounds for use in the treatment of parkinson's disease
PH12021551239A1 (en) Synergistic compositions comprising r-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones and s-2-(substituted-sulfonyl)-hexahydro-pyrrolo[1,2-a]pyrazin-6(2h)-ones in a non-racemic ratio
TW202421104A (zh) 異雙官能化合物及治療疾病之方法
ECSP21040300A (es) Composiciones sinérgicas que comprenden (r)-2-(2-oxopirrolidin-1-il)butanamida y (s)-2-(2-oxopirrolidin-1-il)butanamida en una proporción no racémica